GRIN2D Gene
Introduction <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>Ensembl ID </td>UniProt ID </td>Gene Type </td>OMIM </td>
...
GRIN2D Gene
Introduction <table class="infobox infobox-gene">Gene Symbol </td>Full Name </td>Chromosomal Location </td>NCBI Gene ID </td>Ensembl ID </td>UniProt ID </td>Gene Type </td>OMIM </td>
The GRIN2D gene (Glutamate Ionotropic Receptor NMDA Type Subunit 2D) encodes the GluN2D subunit of N-methyl-D-aspartate (NMDA) receptors, a critical subtype of ionotropic glutamate receptors in the central nervous system. NMDA receptors are ligand-gated calcium channels that play essential roles in synaptic transmission, plasticity, and survival. The GluN2D subunit confers distinct pharmacological and electrophysiological properties to NMDA receptors and is particularly important in brain regions involved in motor control, cognition, and neurodegeneration. [@nmda2023]
Gene Overview
Protein Product The GluN2D protein is a transmembrane receptor subunit that assembles with other NMDA receptor subunits (GluN1, GluN2A-C, GluN3A-B) to form functional receptor complexes. The receptor is a heterotetramer typically composed of two GluN1 subunits and two GluN2 subunits. GluN2D-containing receptors have distinct developmental and regional expression patterns. [@structure2022]
Structure
Extracellular Domain : Ligand-binding domain for glutamate and co-agonistsTransmembrane Segments : Four α-helices that form the ion channel poreC-terminal Domain : Intracellular tail involved in scaffolding and signalingS1 and S2 Regions : Form the agonist binding domainFunction GluN2D-containing NMDA receptors have unique functional properties:
Calcium Permeability : High calcium influx through these receptorsSlow Decay Kinetics : Longer channel open times compared to other GluN2 subunitsMg²⁺ Block Sensitivity : Reduced voltage-dependent magnesium blockRegional Expression : High expression in basal ganglia, hypothalamus, and olfactory bulb
Signaling Pathways
Ca²⁺/Calmodulin-Dependent Pathways : Activation of downstream enzymesCaMKII Activation : Calcium-dependent protein kinase signalingCREB Activation : Transcriptional regulation via cAMP response element-binding proteinSynaptic Plasticity : Role in long-term potentiation and depression [@grind2021]Disease Associations
Alzheimer's Disease GRIN2D is implicated in AD pathophysiology:
NMDA receptor dysfunction contributes to synaptic failure
Altered GluN2D expression in AD brains
Excitotoxicity through excessive calcium influx
Interactions with amyloid-beta signaling [@nmda2023a]
Parkinson's Disease The gene has particular relevance to PD:
High expression in basal ganglia regions affected in PD
Modulation of dopaminergic signaling
NMDA receptor antagonists have therapeutic potential
Role in levodopa-induced dyskinesias [@basal2022]
Other Neurological Conditions
Huntington's Disease : Altered NMDA receptor functionEpilepsy : GRIN2D mutations associated with seizure disordersSchizophrenia : Genetic associations with psychiatric disordersStroke : Excitotoxic cell death via NMDA receptorsMutations
Pathogenic Variants
Polymorphisms
Various SNPs have been associated with neurological disease risk
Studies link GRIN2D variants to schizophrenia susceptibility
Gene-environment interactions are being investigated [@grind2022]
Therapeutic Relevance
Therapeutic Targets
NMDA Receptor Modulators : Compounds that selectively modulate GluN2D-containing receptorsChannel Blockers : Ifenprodil and related compounds show selectivityAllosteric Modulators : Positive and negative allosteric modulators
Drug Development
Ifenprodil : NR2B-selective antagonist (less relevant for GluN2D)E体202 : GluN2D-selective antagonist in developmentCIQ : Positive allosteric modulator of GluN2D [@glundselective2024]Clinical Applications
Neuroprotective strategies targeting excitotoxicity
Treatment of movement disorders
Potential for preventing neurodegeneration
Interactions
Receptor Complex
Interacting Proteins
PSD-95 : Scaffold protein at postsynaptic密度CaMKII : Calcium-dependent kinaseSynGAP : Synaptic Ras GTPase-activating proteinShank : Postsynaptic density scaffolding proteinsSignaling Molecules
PI3K/Akt pathway
MAPK/ERK pathway
PLCγ signaling [@nmda2023b]
Research Directions Current research focuses on:
Developing GluN2D-selective pharmacological tools
Understanding regional specificity of GluN2D function
Exploring neuroprotective strategies
Genetic studies linking GRIN2D to disease
References
[Unknown, NMDA receptor subunits in neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Unknown, Structure and function of GluN2D-containing NMDA receptors (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.04.015)
[Unknown, GRIN2D signaling in the central nervous system (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Unknown, NMDA receptor dysfunction in Alzheimer's disease (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Unknown, Basal ganglia NMDA receptors in Parkinson's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35456789/)
[Unknown, GRIN2D genetic variants and neurological disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Unknown, GluN2D-selective pharmacological agents (2024) (2024)](https://doi.org/10.1038/npharmacol.2024.0123)
[Unknown, NMDA receptor interacting proteins (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/) Show full description